Zhejiang Medicine Co., Ltd. (SHA:600216)
China · Delayed Price · Currency is CNY 12.12
+0.14 (1.17%)
Oct 16, 2026, 3:00 PM CST
Zhejiang Medicine Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,489 | 13,138 | 15,252 | 10,281 | 11,203 | 16,368 | |
Market Cap Growth | -16.76% | -13.86% | 48.35% | -8.23% | -31.56% | 25.59% |
Enterprise Value | 8,848 | 11,060 | 14,305 | 9,752 | 10,751 | 15,886 |
Last Close Price | 12.12 | 13.54 | 15.12 | 10.09 | 10.83 | 15.46 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.44 | 15.04 | 13.14 | 23.93 | 20.76 | 15.66 |
Forward PE | 10.02 | 13.46 | 10.55 | 13.58 | 15.18 | 12.31 |
PS Ratio | 1.28 | 1.48 | 1.63 | 1.32 | 1.38 | 1.79 |
PB Ratio | 0.95 | 1.19 | 1.40 | 1.03 | 1.15 | 1.78 |
P/TBV Ratio | 1.04 | 1.27 | 1.53 | 1.16 | 1.32 | 2.04 |
P/FCF Ratio | 11.15 | 9.13 | 28.55 | - | - | 83.06 |
P/OCF Ratio | 7.46 | 6.97 | 12.47 | 16.21 | 21.52 | 14.40 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.99 | 1.25 | 1.53 | 1.25 | 1.33 | 1.74 |
EV/EBITDA Ratio | 5.83 | 7.05 | 7.11 | 13.32 | 9.19 | 9.09 |
EV/EBIT Ratio | 10.58 | 12.87 | 11.09 | 1222.28 | 21.95 | 13.69 |
EV/FCF Ratio | 8.59 | 7.68 | 26.78 | - | - | 80.62 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.08 | 0.08 | 0.07 | 0.08 | 0.09 | 0.05 |
Debt / EBITDA Ratio | 0.61 | 0.56 | 0.38 | 1.10 | 0.71 | 0.27 |
Debt / FCF Ratio | 0.89 | 0.61 | 1.42 | - | - | 2.42 |
Net Debt / Equity Ratio | -0.25 | -0.23 | -0.14 | -0.10 | -0.11 | -0.19 |
Net Debt / EBITDA Ratio | -2.04 | -1.62 | -0.75 | -1.34 | -0.90 | -1.00 |
Net Debt / FCF Ratio | -2.99 | -1.77 | -2.82 | 6.02 | 2.31 | -8.88 |
Asset Turnover | 0.62 | 0.64 | 0.71 | 0.62 | 0.65 | 0.79 |
Inventory Turnover | 2.86 | 3.00 | 2.70 | 2.69 | 2.81 | 3.30 |
Quick Ratio | 2.97 | 2.13 | 1.67 | 1.39 | 1.40 | 1.30 |
Current Ratio | 4.11 | 2.96 | 2.56 | 2.26 | 2.29 | 2.00 |
Return on Equity (ROE) | 5.54% | 6.93% | 9.79% | 2.81% | 3.84% | 10.28% |
Return on Assets (ROA) | 3.60% | 3.85% | 6.07% | 0.04% | 2.45% | 6.30% |
Return on Invested Capital (ROIC) | 7.40% | 7.67% | 11.82% | 0.07% | 4.49% | 12.30% |
Return on Capital Employed (ROCE) | 6.50% | 7.40% | 11.50% | 0.10% | 4.90% | 12.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.02% | 6.65% | 7.61% | 4.18% | 4.82% | 6.39% |
FCF Yield | 8.97% | 10.96% | 3.50% | -1.58% | -4.06% | 1.20% |
Dividend Yield | 2.31% | 2.02% | 2.33% | 1.32% | 1.45% | 1.93% |
Payout Ratio | 46.66% | 43.13% | 14.67% | 44.67% | 65.07% | 24.88% |
Buyback Yield / Dilution | 0.83% | 0.42% | -0.46% | 0.91% | -0.47% | -0.26% |
Total Shareholder Return | 3.14% | 2.44% | 1.88% | 2.23% | 0.98% | 1.67% |